Introduction
Treatment of short stature with human pituitary growth hormone In 1985 pituitary growth hormone treatment became associated with fatal Creutzfeldt-Jakob disease, including one case in the United Kingdom,`8 and such preparations were withdrawn almost world wide. Our study was then instigated to review mortality and monitor prospectively the long term health of patients in the United Kingdom treated with growth hormone. We report the mortality and cancer registration data from 1959 to December 1990.
Patients and methods
Patients treated with growth hormone from 1959 to 1985 in the United Kingdom and Eire were identified from Health Services Human Growth Hormone Committee records. These were collated with the NHS central register and registrar's offices in Scotland and Northern Ireland to ascertain deaths and cancer registrations and "flag" survivors so that future deaths and cancer registrations could be notified. In addition, deaths from Creutzfeldt-Jakob disease and similar neurological disorders from 1971 to 1984 were reviewed; none of these patients had been treated with growth hormone. About 40 patients from the United Kingdom received commercial growth hormone preparations and were excluded from the study, as were patients who received only recombinant growth hormone. 15 Cause of death was determined from death certifi- The mortality findings for patients with craniopharyngioma were no better than for those with malignant intracranial tumours, representing late tumour recurrence for both groups. Deaths among patients with craniopharyngioma were apparently not reduced by early radiotherapy yet cranial irradiation may have contributed to two fatal second intracranial tumours. Children with tumours of the central nervous system seemed to have an increased risk of developing a second tumour in the central nervous system,24 and development of second tumours within radiotherapy fields after latencies such as the 6-10 years found by us has been reported. 29 Our study could not assess not-fatal tumour recurrences, and a control group not treated with growth hormone was not available. We cannot therefore conclude whether growth hormone contributed to tumour recurrence and death. Studies of subgroups of these patients showed no excess recurrence of commoner intracranial tumours compared with patients who had not received growth hormone'920; small studies suggest no increased risk of tumour recurrence.26 27 First intracranial tumours were identified in 10 patients with "idiopathic" growth hormone deficiency. These were probably causally related to the hormone deficiency but undetectable at the time. Improved imaging now permits earlier localisation of tumours although clinical features, such as epilepsy, delayed puberty, and diabetes insipidus, present in some of these cases, should alert doctors to the need for regular reassessment and long term follow Up.- 29 Deaths from hypopituitarism should be preventable. The risk of hypoglycaemia in young children, aggravated by acute infection, and the added complication of diabetes insipidus cannot be overemphasised. Education should minimise the risks of hypopituitary crises. The importance of periodic evaluation of pituitary function in growth hormone deficient patients is shown by the death of one boy whose panhypopituitarism evolved over several years. Morbidity associated with non-fatal metabolic disturbances due to hypopituitarism needs to be reviewed.
There have been recent reports of leukaemia developing after growth hormone treatment9'4 but we identified no new cases of leukaemia; both instances of relapse were at high risk of further relapse. Of four extracranial malignancies two were second primary tumours (osteosarcoma and basal cell carcinoma). The first (reported previously as osteosarcoma of the femur25) had only cranial irradiation and neither had chemotherapy. Without a control group it is impossible to assess the relevance of growth hormone deficiency or treatment to increased risk of tumour formation. Short stature is associated with conditions with increased risk of malignancy and such patients have received growth hormone. These conditions include Fanconi's anaemia (two patients died from narrow aplasia and infection), neurofibromatosis, Bloom syndrome, Kearns-Sayre syndrome, and bilateral retinoblastoma. These patients should be monitored with particular care for tumour development.
World wide there have now been 16 Large epidemics of dengue haemorrhagic fever among children are frequently reported in the tropics, particularly in South East Asia and the Caribbean, with an associated mortality of 2-10%. This syndrome is rare in adults and has not, we believe, been reported before in travellers returning to the United Kingdom. We presume that our patients acquired dengue haemorrhagic fever as a result of infection with a second serotype of dengue virus after a delay of many years since their first exposure to the virus. This potential problem should be remembered whenever people return to the tropics, and they should be
